Novanta Inc. (NOVT) | The Buildout — AI Infrastructure
The Verdict
Novanta sells the precision parts that go inside other companies' machines. Its automation arm supplies laser beam steering, laser sources, precision motion and air bearing spindles into the equipment that makes and packages semiconductors and into robots and automated factories. Its medical arm sells insufflators, endoscopic pumps, imaging and operating-room technologies, and — after the acquisition management describes as its largest to date — recurring surgical consumables. The AI buildout reaches Novanta indirectly: its components sit inside the tools and robots that chipmakers, equipment OEMs and warehouse operators buy, so demand rides those customers' capital budgets rather than data-center operators directly.
| Market Cap | — |
| Revenue (TTM) | $1.0B |
| Revenue Growth | +7.6% |
| EBITDA Margin (TTM) | 16.4% |
| Net Cash | $436M |
| Earnings Beats | 5 of 7 |
| P/E (TTM) | — |
| EV/EBITDA (TTM) | — |
What We Like
- Organic growth inflected from 3% in Q1 2026 to 9% in Q2 2026, with all four business units growing; the full-year organic outlook was raised to up to 7% and reported growth is guided to more than 15%.
- Full-year 2026 guidance was raised twice — revenue to approximately $1,130–$1,140M, adjusted EBITDA to $273–$278M and adjusted EPS to $3.68–$3.74.
- Management estimates GenAI technologies and infrastructure at about 17% of Q2 2026 revenue, growing roughly 25% year over year, up from about 15% growing about 20% in Q1; the air bearing spindle business is booked for the next two years, with China capacity being doubled and partially funded by customers.
- Automation Enabling Technologies adjusted gross margin rose to about 53%, up 450 basis points year over year; two factory closures were completed in Q2 2026 and two more were announced.
- Riverpoint roughly doubles recurring medical consumables to approximately $300 million, moves consumables to roughly 25% of revenue annualized and lifts medical end-market exposure to 60%; year-to-date operating cash flow of $117M already exceeds all of fiscal 2025.
What We’re Watching
- Medical Solutions adjusted gross margin fell to about 41% in Q2 2026, down 290 basis points year over year, and book-to-bill was 0.79. Management expects margins to expand materially in Q3 and says the four-quarter rolling book-to-bill is above 1.
- The guided step-up to about 48% adjusted gross margin in the second half, and a further 100 basis points in 2027, depends on completing two more factory closures by the end of Q1 2027 and on integrating Riverpoint; management acknowledges execution risk.
- Tariffs remain a net negative position, and management says surcharging will not completely absorb the new tariff increases. Tariff refunds are excluded from guidance.
- Leverage steps up in Q3 2026 to gross debt just north of $800M and gross pro forma leverage of 2.7x, from negative 2x net leverage in Q2, while Precision Medicine is not expected to return to growth until late 2027.
The thesis reads as strengthening on the operating record: two quarters of organic inflection, a full-year guide raised twice, record cash generation, and a portfolio shift toward recurring medical consumables. It is also carrying more complexity at once — the largest acquisition in company history, two more factory closures, two MRP system implementations and a leverage step-up to 2.7x gross pro forma in Q3. The open question is whether the guided second-half margin step-up lands while Medical Solutions margins recover.
Earnings Beat
Novanta reported Q2 2026 revenue of $265.8 million, up from $241.0 million a year earlier — 10% reported growth and 9% organic. Management reported an adjusted gross margin of 47%, up 100 basis points year over year, and adjusted EBITDA of $60.7 million at roughly a 23% margin, up more than 16%. The standout was cash: second-quarter operating cash flow was $65 million against $15 million a year earlier, and year-to-date operating cash flow of $117 million already exceeds all of fiscal 2025.
| Metric | Q2 FY2026 | Q1 FY2026 | Q2 FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $266M | $258M | $241M | +10.3% |
| Gross margin | 45.5% | 41.8% | 41.4% | +410bps |
| EBITDA | $33M | $44M | $43M | −24.1% |
| EPS | $0.30 | $0.51 | $0.12 | +143.4% |
| Vitality index (new-product share of sales) | ~29% of sales | n/a | 21% | +~8 pts y/y |
| GenAI revenue exposure (management estimate) | ~17% of revenue | ~15% | n/a | +25% y/y |
It roughly doubles our recurring medical consumable business to approximately $300 million from about 15% of revenue to roughly 25% annualized.— Matthijs Glastra, CEO, 2026-08-06
Management tone: Management's tone escalated across the two most recent calls. In Q1 2026 they described "momentum is building" and called it "a trajectory, not a data point"; in Q2 2026 they called it "our strongest organic growth and cash flow growth in the last 3 years" and said "Novanta's trajectory from here is up." They paired that with a continuing macro caveat — "the macro remains complex" — and stayed direct on hard numbers, quantifying the EPS bridge and the gross-margin algorithm. They declined to size the humanoid servo-drive order or the 2027 GenAI growth rate, and reframed Medical's 0.79 book-to-bill around a four-quarter rolling average they say is above 1.
Management Guidance
Management guides FY2026 revenue to approximately $1,130–$1,140M, reported growth greater than 15% and organic growth of up to 7%. Adjusted EBITDA is guided to $273–$278M (24%–26% year-over-year growth, including around $25M from Riverpoint) and adjusted EPS to $3.68–$3.74 (12%–14% growth). Adjusted gross margin is guided to around 47%, operating expenses to 27%–28% of sales, R&D to close to $100M (8.5%–8.7% of sales), and the tax rate to just north of 21%. For Q3 2026 management guides revenue of $300–$304M, adjusted gross margin of about 48%, adjusted EBITDA of $74–$77M and adjusted EPS of $0.95–$1.00. Riverpoint is expected to add $60–65M of revenue, $25M of EBITDA and $0.06 of EPS in the second half, with about $35M of revenue in Q3. Any tariff refunds are excluded from guidance.
Trajectory
Reported revenue moved from $241.0 million in Q2 2025 to $265.8 million in Q2 2026, with organic growth inflecting from 3% in Q1 2026 to 9% in Q2. The margin picture splits by segment: Automation Enabling Technologies adjusted gross margin rose to about 53% in Q2, up 450 basis points year over year, on productivity, pricing and surcharging and a richer new-product mix, while Medical Solutions fell to about 41%, down 290 basis points, on lower-margin precision medicine mix and temporary transformation costs. Cash generation stepped up sharply: Q2 operating cash flow was $65 million against $15 million a year earlier, and year-to-date operating cash flow of $117 million already exceeds the full-year 2025 figure.
The Model
The model projects FY+1 revenue of $1,140M with EBITDA of $242M (21.2% margin), and FY+2 revenue of $1,306M with EBITDA of $298M (22.8% margin). The near-term projection sits against management's raised full-year guidance and the guided step-up in adjusted gross margin to around 48% in the second half, supported by the two completed factory closures and a partial-year Riverpoint contribution. FY+2 carries the annualized benefit of Riverpoint, which closed at the end of July 2026, plus the further 100 basis points of gross-margin improvement management guides for 2027.
| Metric | FY2025 | Next FY (E) | Following FY (E) |
|---|---|---|---|
| Revenue | $980M | $1.1B | $1.3B |
| YoY Growth | — | +16.3% | +14.6% |
| EBITDA | $179M | $242M | $298M |
| EBITDA Margin | 18.2% | 21.2% | 22.8% |
Projections are the median of 5 independent model runs. The model’s revenue sits 17.3% above analyst consensus.
Management guides FY2026 revenue to approximately $1,130–$1,140M, reported growth greater than 15% and organic growth of up to 7%. Adjusted EBITDA is guided to $273–$278M (24%–26% year-over-year growth, including around $25M from Riverpoint) and adjusted EPS to $3.68–$3.74 (12%–14% growth). Adjusted gross margin is guided to around 47%, operating expenses to 27%–28% of sales, R&D to close to $100M (8.5%–8.7% of sales), and the tax rate to just north of 21%. For Q3 2026 management guides revenue of $300–$304M, adjusted gross margin of about 48%, adjusted EBITDA of $74–$77M and adjusted EPS of $0.95–$1.00. Riverpoint is expected to add $60–65M of revenue, $25M of EBITDA and $0.06 of EPS in the second half, with about $35M of revenue in Q3. Any tariff refunds are excluded from guidance.
What Could Go Right — and Wrong
- Riverpoint delivers at or above the guided $60–65M of second-half revenue and $25M of EBITDA, with gross-margin accretion visible in the consolidated numbers.
- The two additional factory closures complete on schedule by the end of Q1 2027, converting into the guided ~48% second-half gross margin and the 100 basis points of improvement in 2027.
- The GenAI bucket sustains roughly 25% growth and management puts a number on 2027, turning an early, unquantified vector into a forecastable one.
- Humanoid servo-drive orders move from customer testing and learning facilities into commercial deployment, lifting Robotics & Automation from a small base.
- Medical Solutions gross margin recovers in Q3 and Precision Medicine turns earlier than the guided late-2027 timeframe, easing the segment mix drag.
- Execution on the additional site closures slips, breaking the 47% to ~48% to higher 2027 gross-margin path management has laid out.
- Medical Solutions gross margin stays near 41% and book-to-bill remains below 1, indicating a structural rather than timing issue in the segment the company is expanding.
- The AI and semiconductor capital-equipment cycle cools, slowing the GenAI bucket and the air bearing spindle backlog that management says is booked for two years.
- Riverpoint's first public-company close misses the guided contribution or integration costs overrun, against a leverage step-up to 2.7x gross pro forma.
- Tariffs escalate faster than surcharging and productivity can offset, and customer concentration in medical rises further as Riverpoint lifts medical to about 60% of revenue.
Looking Ahead
The next twelve months are about converting promises into numbers. Q3 2026 carries the first Riverpoint contribution and a guided step-up in adjusted gross margin to about 48%; two more factory closures are due by the end of Q1 2027; the delayed EUV/DUV new-business ramp is expected to begin shipping in the second half of 2026 and be more pronounced in 2027. Management expects humanoid applications to become more meaningful in 2027, and Precision Medicine is not expected to return to growth until late 2027. Cash conversion is guided to step down in Q3 largely because of the Riverpoint acquisition, but management still points to a record cash-flow year.
- Q3 2026First Riverpoint quarter — Guided revenue $300–304M, ~48% gross margin, EBITDA $74–77M.
- H2 2026EUV/DUV ramp begins — Delayed new-business program starts shipping; more pronounced in 2027.
- End Q1 2027Two factory closures complete — Full production moves and transfers; underpins the 2027 margin path.
- 2027Gross margin +100 bps — Management guides another 100 basis points of improvement in 2027.
- 2027Humanoid ramp 'more meaningful' — Shift from training facilities toward commercial deployment.
- Late 2027Life-sciences return to growth — Precision Medicine expected to return to sustained growth.
Financials
Annual Summary
| Metric | FY2024 | FY2025 | TTM | YoY |
|---|---|---|---|---|
| Revenue | $949M | $980M | $1.0B | +3.3% |
| Gross Margin | 44.4% | 41.6% | 42.5% | 282bps |
| EBITDA | $166M | $179M | $169M | +7.5% |
| EBITDA Margin | 17.5% | 18.2% | 16.4% | +72bps |
| Net Income | $64M | $54M | $62M | -16.0% |
| Free Cash Flow | $141M | $48M | $114M | — |
| Net Cash | — | — | — | — |
Key Ratios (Trailing)
- P/E TTM—
- EV/EBITDA TTM—
- EV/Revenue TTM—
- Price/FCF TTM—
- Gross Margin (TTM)42.5%
- EBITDA Margin (TTM)16.4%
- Net Margin (TTM)6.0%
- ROIC7.2%
- FCF Conversion67.6%
- SBC / Revenue3.4%
The Company
Novanta is a global supplier of core technology solutions to medical, life-science and advanced-industrial OEMs, organized around four growth platforms it names as precision medicine, precision manufacturing, robotics and automation, and advanced surgery. It reports in two segments. Automation Enabling Technologies supplies laser beam steering and scanning, laser sources, robotic and precision motion, and air bearing spindles; Medical Solutions supplies insufflators and endoscopic pumps with related disposables, imaging, identification and RFID, advanced motion control, light engines and integrated operating-room technologies. The AI buildout reaches the company through the automation segment, which sells into semiconductor equipment, advanced packaging and robotics rather than to data-center operators directly.
Novanta manufactures across its own footprint. The 10-K lists 14 manufacturing sites — eight in Automation Enabling Technologies and six in Medical Solutions — across the United States, the United Kingdom, China, Germany, Spain and the Czech Republic, while management said on the Q1 2026 call that the company has "more than 20 facilities"; the material does not reconcile the two. The company is consolidating that footprint: it completed two factory closures in Q2 2026, announced two more for completion by the end of Q1 2027, and is implementing two MRP systems as part of a program it says reduces complexity and asset intensity and "dramatically reduces or eliminates our sensitivity to trade disruptions."
Business Segments
Competitive Landscape
The material does not describe Novanta's competitive landscape in the company's own words. What it does carry are positioning claims: management says its technology is designed into customers' products "for the better part of the decade," that it is "the #1 by far leading" supplier of the air bearing spindles used to mechanically drill thick AI GPU boards, and that it is "the only servo drive manufacturer as far as we are aware" selected for the NVIDIA Halos AI Systems Inspection Lab. Competitor names appear only in a supply-chain graph, tagged as inferred rather than documented.
- Listed as a competitor in the supply-chain graph; no Novanta-specific commentary in the material.
- Listed as a competitor in the supply-chain graph; no Novanta-specific commentary in the material.
- Appears both as a competitor and as a customer/supplier in the graph (laser sources and optical components); no Novanta-specific commentary.
- Listed as a competitor in the supply-chain graph; no Novanta-specific commentary in the material.
- Appears as both a customer (beam delivery optics) and a competitor in the graph; no Novanta-specific commentary.
Supply Chain
Novanta sits upstream: it sells precision motion, laser and medical subsystems to equipment and device OEMs, not to data-center operators. No supplied neighbor transcript mentions Novanta by name, so the read-through from the chain is ecosystem capex context.
Related companies
See all Chip Making companies → · How this layer works: Chapter 1, The Chip →
More on NOVT: Earnings recap